Achaogen (AKAO) : Traders are bullish on Achaogen (AKAO) as it has outperformed the S&P 500 by a wide margin of 13.32% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 10.19%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 10.37% in the last 1 week, and is up 12.71% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 10.8% and the 50-Day Moving Average is 19.02%.The 200 Day SMA reached 22.76%
Achaogen (NASDAQ:AKAO): After opening at $4.54, the stock dipped to an intraday low of $4.46 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $5.22 and the buying power remained strong till the end. The stock closed at $4.79 for the day, a gain of 5.04% for the day session. The total traded volume was 720,837. The stocks close on the previous trading day was $4.79.
Achaogen (AKAO) : Average target price received by Achaogen (AKAO) is $10.33 with an expected standard deviation of $0.58. The most aggressive target on the stock is $11, whereas the most downbeat target is $10. 3 financial analysts are currently covering the stock.
Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multidrug resistant (MDR) gram-negative infections. The Companys lead product, plazomicin, is used to treat bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE), and is in Phase III Clinical trials. In addition to plazomicin, the Companys research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections. The first is a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria and the second is a therapeutic antibody program to generate mAbs (monoclonal antibodies) that can be deployed as a monotherapy to treat infections caused by MDR Acinetobacter baumannii and other gram-negative pathogens.